Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT06375629 | ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer(ES-HIFU) | terminated | — | 14 | EDAP TMS S.A.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)(WB-LuPSMA) | terminated | — | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer(RAD 1805) | terminated | Phase 2 | 9 | University of Alabama at BirminghamOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT04421222 | Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer(EPI-7386) | terminated | Phase 1 | 71 | ESSA PharmaceuticalsINDUSTRY | 2 | Feb 28, 2025 | clinicaltrials |
| NCT05075577 | EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC | terminated | Phase 1 / Phase 2 | 77 | ESSA PharmaceuticalsINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT05224869 | Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer | terminated | N/A | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 28 | Accutar Biotechnology IncINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | terminated | Phase 3 | 158 | CR-CSSS Champlain-Charles-Le MoyneOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | terminated | Phase 1 | 43 | Seagen Inc.INDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT05123300 | PRISMA-PET - Primary Staging of Prostate Cancer With PSMA | terminated | N/A | 385 | Odense University HospitalOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05295927 | A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | terminated | Phase 1 | 3 | Janssen Research & Development, LLCINDUSTRY | 2 | Feb 3, 2025 | clinicaltrials |
| NCT03465579 | Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.(BIOPSTAGE) | terminated | N/A | 261 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer | terminated | Phase 4 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05709535 | PSMA-PET/CT Registry | terminated | — | 128 | AHS Cancer Control AlbertaOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | terminated | Phase 1 / Phase 2 | 21 | Oncternal Therapeutics, IncINDUSTRY | 2 | Dec 11, 2024 | clinicaltrials |
| NCT05826470 | Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging | terminated | N/A | 4 | Genesis Research LLCNETWORK | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06016504 | Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer | terminated | N/A | 18 | Mayo ClinicOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04291664 | PK and Dose Escalation and Expansion Study of DST-2970 | terminated | Phase 1 | 26 | DisperSol Technologies, LLCINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 6 | University of California, San DiegoOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | terminated | Phase 1 / Phase 2 | 30 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 26, 2024 | clinicaltrials |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | terminated | Phase 3 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | terminated | Phase 1 | 60 | University of ChicagoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00773773 | Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer | terminated | N/A | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | terminated | Phase 3 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 30 | Biosplice Therapeutics, Inc.INDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | terminated | Phase 1 | 14 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC | terminated | Phase 1 | 11 | Swiss Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT04293406 | pCHIP: Prostate Cancer Health Impact Program | terminated | — | 82 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers(Immune PDX) | terminated | — | 3 | Duke UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 10 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04907227 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension | terminated | Phase 3 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | terminated | Phase 2 | 8 | Jodi Layton, MDOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer | terminated | Phase 2 | 16 | Effector TherapeuticsINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT03066154 | Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer(DOP) | terminated | Phase 1 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03632655 | A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches | terminated | N/A | 38 | Weill Medical College of Cornell UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2025source: clinicaltrials